| Recruiting | Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) NCT07481734 | Hudson Biotech | Phase 2 |
| Not Yet Recruiting | Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis NCT02933554 | Keith Pereira, MD: | N/A |
| Withdrawn | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH NCT06692283 | Sagimet Biosciences Inc. | Phase 3 |
| Withdrawn | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis NCT06594523 | Sagimet Biosciences Inc. | Phase 3 |
| Active Not Recruiting | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) NCT06465186 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) NCT06342947 | Aligos Therapeutics | Phase 2 |
| Active Not Recruiting | Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis NCT05979779 | Rivus Pharmaceuticals, Inc. | Phase 2 |
| Completed | Conditionally Increased Output (CIO) Enhanced Ultrasound System NCT05792423 | Massachusetts General Hospital | N/A |
| Completed | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6 NCT05877547 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steato NCT05731596 | Tanta University | Phase 3 |
| Completed | Dose Escalation Study of Kylo-0603 in Healthy Subjects NCT06365580 | Kylonova (Xiamen) Biopharma co., LTD. | Phase 1 |
| Recruiting | Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis NCT05720663 | Virginia Commonwealth University | — |
| Recruiting | Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans NCT05526144 | VA Office of Research and Development | Phase 2 |
| Completed | A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic NCT05809934 | AstraZeneca | Phase 2 |
| Completed | Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis NCT05680233 | Oasis Pharmaceuticals, LLC | Phase 1 |
| Unknown | A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy NCT05655221 | Tasly Biopharmaceuticals Co., Ltd. | Phase 1 |
| Completed | Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Live NCT05560607 | AstraZeneca | Phase 1 |
| Completed | Vitamin E Dosing Study NCT04801849 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Unknown | Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis NCT05733897 | National Taiwan University Hospital | — |
| Unknown | A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D a NCT03970031 | Cirius Therapeutics, Inc. | Phase 3 |
| Recruiting | Metabolic Pathology of Pediatric NAFLD NCT05430178 | University of Oklahoma | N/A |
| Recruiting | Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease NCT05330923 | Peking Union Medical College Hospital | — |
| Completed | Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study NCT05309642 | Ewha Womans University Mokdong Hospital | N/A |
| Unknown | Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease NCT05084404 | Yokohama City University | Phase 2 |
| Completed | Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis NCT05011305 | Zydus Therapeutics Inc. | Phase 2 |
| Unknown | Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D) NCT05029583 | LMC Diabetes & Endocrinology Ltd. | N/A |
| Completed | Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Non NCT04971785 | Gilead Sciences | Phase 2 |
| Completed | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001 NCT04944992 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | FTIH Study of ECC0509 in Healthy Volunteers NCT05012423 | Eccogene | Phase 1 |
| Unknown | FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis NCT04710524 | Future Medicine | Phase 2 |
| Active Not Recruiting | Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study NCT04550481 | Northwestern University | Phase 2 |
| Completed | First-in-Human Study of SRT-015 in Healthy Subjects. NCT04887038 | Syneos Health | Phase 1 |
| Completed | Noninvasive Biomarkers of Metabolic Liver Disease 1.1 NCT04828551 | Massachusetts General Hospital | N/A |
| Completed | CM-101 in NASH Patients - The SPLASH Study NCT05824156 | ChemomAb Ltd. | Phase 2 |
| Active Not Recruiting | Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes NCT04595474 | Joslin Diabetes Center | — |
| Recruiting | Low-Dose Pioglitazone in Patients With NASH (AIM 2) NCT04501406 | University of Florida | Phase 2 |
| Terminated | A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) NCT04583423 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability NCT04561245 | Altimmune, Inc. | Phase 1 |
| Terminated | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) NCT04565717 | Alnylam Pharmaceuticals | Phase 1 |
| Completed | Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Pr NCT04399538 | Pfizer | Phase 2 |
| Terminated | Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alco NCT04147195 | Novartis Pharmaceuticals | Phase 2 |
| Withdrawn | Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH) NCT04216693 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Completed | To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants NCT04389775 | Sciwind Biosciences APAC CO Pty. Ltd. | Phase 1 |
| Completed | Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) NCT04210245 | NGM Biopharmaceuticals, Inc | Phase 2 |
| Completed | Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease NCT04235205 | Yokohama City University | Phase 2 |
| Completed | Safety and Tolerability of Oral Proglumide for NASH NCT04152473 | Georgetown University | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH NCT04342793 | AngioLab, Inc. | Phase 2 |
| Completed | A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) NCT04166773 | Eli Lilly and Company | Phase 2 |
| Completed | Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the NCT04137055 | Guangdong Raynovent Biotech Co., Ltd | Phase 1 |
| Completed | Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease NCT04031729 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic S NCT03987074 | Gilead Sciences | Phase 2 |
| Unknown | Norursodeoxycholic Acid vs. Placebo in NASH NCT05083390 | Dr. Falk Pharma GmbH | Phase 2 |
| Unknown | Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study NCT04012242 | Tokyo Medical University | — |
| Completed | Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1 NCT04389593 | University of California, San Diego | — |
| Completed | Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NA NCT05343780 | Natural Wellness Egypt | Phase 2 |
| Completed | Dapagliflozin Efficacy and Action in NASH NCT03723252 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Completed | De Novo Lipogenesis in Severity of NAFLD NCT03683589 | University of Missouri-Columbia | — |
| Recruiting | Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance NCT05165706 | Stanford University | N/A |
| Terminated | Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH) NCT03676231 | Second Genome | Phase 2 |
| Completed | A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) NCT03656744 | HighTide Biopharma Pty Ltd | Phase 2 |
| Completed | An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels NCT03674476 | Bristol-Myers Squibb | Phase 1 |
| Unknown | Liver Fibrosis in Peri-menopausal Women NCT03602573 | Chang Gung Memorial Hospital | — |
| Completed | A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 L NCT03486899 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cir NCT03486912 | Bristol-Myers Squibb | Phase 2 |
| Not Yet Recruiting | Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese NCT03282305 | Great China Fatty Liver Consortium Limited | — |
| Completed | Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Particip NCT03449446 | Gilead Sciences | Phase 2 |
| Completed | A Study of Experimental Medication BMS-986036 Given to Healthy Participants NCT03445208 | Bristol-Myers Squibb | Phase 1 |
| Completed | Feasibility of VIIT in Adults With NASH NCT03861819 | Duke University | N/A |
| Terminated | Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and NCT03332940 | Navidea Biopharmaceuticals | Phase 1 |
| Terminated | A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Avera NCT03329885 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Non NCT03439254 | Intercept Pharmaceuticals | Phase 3 |
| Completed | Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) NCT03248882 | Pfizer | Phase 2 |
| Completed | The Liver Health Study for Patients with NAFLD NCT03151798 | University of Missouri-Columbia | N/A |
| Completed | Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis NCT03061721 | Zydus Therapeutics Inc. | Phase 2 |
| Terminated | AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adult NCT03028740 | Tobira Therapeutics, Inc. | Phase 3 |
| Terminated | Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohep NCT03059446 | Tobira Therapeutics, Inc. | Phase 2 |
| Terminated | Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibros NCT03053050 | Gilead Sciences | Phase 3 |
| Withdrawn | A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatit NCT03163810 | Erchonia Corporation | N/A |
| Terminated | Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (N NCT03053063 | Gilead Sciences | Phase 3 |
| Completed | A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes NCT03068078 | Odense University Hospital | N/A |
| Withdrawn | A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes NCT02769091 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | Predictable MR Index for Nonalcoholic Steatohepatitis (NASH) NCT03375008 | Korea University Guro Hospital | N/A |
| Unknown | Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD NCT03725631 | Korea University Guro Hospital | N/A |
| Recruiting | A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions NCT02815891 | Target PharmaSolutions, Inc. | — |
| Unknown | Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric Surgery NCT02792634 | RWTH Aachen University | — |
| Completed | Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers NCT05983328 | Sinew Pharma Inc. | Phase 1 |
| Unknown | NASH: Non-invasive Diagnostic Markers and Imaging NCT02717000 | Maastricht University Medical Center | — |
| Completed | Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) NCT02633956 | Intercept Pharmaceuticals | Phase 2 |
| Completed | Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis NCT02510599 | Melinta Therapeutics, Inc. | Phase 2 |
| Unknown | A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic St NCT02574325 | Arisaph Pharmaceuticals Inc | Phase 2 |
| Completed | CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial NCT02654977 | University of Michigan | Phase 2 |
| Completed | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Adv NCT02421094 | Galectin Therapeutics Inc. | Phase 2 |
| Completed | JKB-121 for the Treatment of Nonalcoholic Steatohepatitis NCT02442687 | Manal Abdelmalek | Phase 2 |
| Completed | Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH NCT02412540 | Children's Hospital Medical Center, Cincinnati | N/A |
| Completed | Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Pati NCT02210715 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 |
| Unknown | Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis NCT02307344 | Hillel Yaffe Medical Center | N/A |
| Unknown | Probiotics in the Treatment of NAFLD NCT02764047 | Federal University of Health Science of Porto Alegre | N/A |
| Completed | Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Pa NCT02217475 | Tobira Therapeutics, Inc. | Phase 2 |
| Completed | A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases NCT02077374 | Conatus Pharmaceuticals Inc. | Phase 2 |
| Completed | Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS) NCT01919294 | Sheffield Teaching Hospitals NHS Foundation Trust | Phase 2 |
| Completed | Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease NCT01828528 | Sheba Medical Center | — |
| Completed | Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients NCT04462081 | University of California, San Diego | — |
| Completed | Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome NCT02083367 | OSF Healthcare System | — |
| Withdrawn | Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis NCT01466894 | Immuron Ltd. | Phase 2 |
| Completed | Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steato NCT01679197 | University of Michigan | Phase 2 |
| Terminated | Rifaximin in Fatty Liver Disease NCT01355575 | Imperial College London | Phase 4 |
| Completed | Anti-Fibrotic Effects of Losartan In Nash Evaluation Study NCT01051219 | Newcastle-upon-Tyne Hospitals NHS Trust | Phase 3 |
| Completed | Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes NCT01399645 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Terminated | Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes NCT01260246 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Completed | Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis NCT01094158 | Galmed Medical Reserch | Phase 2 |
| Completed | Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic NCT01205087 | Hadassah Medical Organization | Phase 2 |
| Completed | Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis NCT01237119 | University of Birmingham | Phase 2 |
| Completed | Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and NCT01002547 | VA Office of Research and Development | Phase 4 |
| Completed | Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis NCT01066364 | University of California, San Diego | Phase 2 |
| Completed | Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease NCT01016418 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis NCT00820651 | Catalysis SL | Phase 3 |
| Completed | University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial NCT00994682 | University of Florida | Phase 4 |
| Terminated | Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity NCT00878592 | University of Pittsburgh | N/A |
| Completed | Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (N NCT00740610 | Gilead Sciences | Phase 2 |
| Completed | PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD NCT00794716 | Norgine | Phase 2 |
| Unknown | Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoh NCT00699036 | Brooke Army Medical Center | Phase 2 |
| Completed | Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis NCT00509418 | Catalysis SL | Phase 3 |
| Completed | Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD. NCT00586313 | Indiana University | N/A |
| Unknown | Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infecti NCT00842205 | Charles University, Czech Republic | N/A |
| Completed | Pentoxifylline in Patients With Nonalcoholic Steatohepatitis NCT00590161 | Case Western Reserve University | Phase 2 |
| Completed | The Role of Leptin Receptors in NASH NCT00583999 | University of California, Davis | — |
| Completed | Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH NCT00267670 | Northwestern University | Phase 2 / Phase 3 |
| Unknown | Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepat NCT00152711 | University Hospital, Angers | N/A |
| Completed | Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers NCT00856869 | Norgine | Phase 1 / Phase 2 |
| Completed | Effects of Alanine in Patients With Nonalcoholic Steatohepatitis NCT00586885 | Keith D Lindor, M.D. | N/A |
| Completed | Fatty Acids, Genes and Microbiota in Fatty Liver NCT02148471 | Johane Allard | — |
| Completed | Betaine in Patients With Nonalcoholic Steatohepatitis NCT00586911 | Mayo Clinic | Phase 2 |
| Completed | Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) NCT00227110 | The University of Texas Health Science Center at San Antonio | Phase 4 |
| Completed | Treatment of Nonalcoholic Steatohepatitis With Pioglitazone NCT00013598 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |